2 terminated, 2 unknown. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 2, Unknown 2 |
Follow KH902 fusion protein: new trials by email Literature Review of KH902 fusion protein trials Research Report on KH902 fusion protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Chengdu Kanghong Biotech Co., Ltd. | 1157 | 2018-12-21 | 2021-06-23 |
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Chengdu Kanghong Biotech Co., Ltd. | 1157 | 2018-09-25 | 2021-06-24 |
| Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) Conbercept, Sham injection, Laser - Diabetic Macular Edema | Phase 3 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 248 | 2014-07-01 | 2016-01-06 |
| A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV conbercept, Fixed, conbercept, PRN, sham injection - Choroid Neovascularization Secondary to Degenerative Myopia | Phase 3 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 176 | 2012-08-01 | 2014-06-04 |
Chengdu Kanghong Biotech Co., Ltd. (4)
China (3) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1)